Irinotecan Actavis

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Actavis, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It is employed in oncology to treat metastatic colorectal cancer, as adjuvant therapy for colon cancer, and in combination regimens for small cell lung cancer.

GNH USA supplies Irinotecan Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Irinotecan is used in chemotherapy protocols targeting cancers that rely on rapid DNA replication.

Metastatic colorectal cancer: combined with other agents to improve overall survival in patients with advanced disease. Adjuvant colon cancer: administered after surgical resection to reduce recurrence risk. Small cell lung cancer: incorporated into multi‑drug regimens to enhance response rates in extensive‑stage disease.

Irinotecan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities. - Decreased appetite: reduced food intake during therapy.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent medical attention. - Severe colitis or watery diarrhea leading to dehydration. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Severe abdominal pain: may indicate intestinal toxicity. - Electrolyte disturbances: especially hypokalemia and hypomagnesemia.

Before initiating Irinotecan therapy, clinicians should observe several safety measures.

Monitor blood counts: perform regular complete blood count tests to detect neutropenia. Assess liver function: evaluate hepatic enzymes because metabolism occurs in the liver. Avoid use in patients with known hypersensitivity to irinotecan or its excipients. Use caution in patients with bowel obstruction or pre‑existing diarrhea. Adjust dose in renal impairment: consider reduced dosing for decreased clearance. Store at ambient temperature: keep in original container, protect from light and moisture.

Irinotecan can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce SN‑38 exposure. - Concurrent myelosuppressive chemotherapy (e.g., cyclophosphamide): increases risk of severe bone‑marrow suppression. - High‑dose loperamide or other antidiarrheals that alter gut motility: can exacerbate irinotecan‑induced diarrhea.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may increase SN‑38 levels. - Warfarin: potential for altered anticoagulation parameters. - NSAIDs: may increase risk of gastrointestinal toxicity. - UGT1A1 polymorphism affecting SN‑38 glucuronidation: monitor for increased toxicity.